On June 7, 2026, Novo Nordisk announced that Wegovy® (semaglutide) tablets 25 mg had surpassed three million prescriptions in the United States since their launch just over five months earlier. The company described the milestone as one of the strongest U.S. pharmaceutical launches by volume on record. For an industry accustomed to injectable GLP-1 dominance, the oral formulation's explosive uptake signals a seismic shift — one that carries profound implications for API suppliers, CDMO partners, and the entire peptide manufacturing ecosystem.
One prescription filled every five seconds. That is the mathematical reality behind Novo Nordisk's announcement. The Wegovy pill — the only oral peptide GLP-1 receptor agonist with no drug-drug restrictions in its label — has bypassed the injection barrier that limited GLP-1 adoption for years. Patient preference surveys consistently show that 60–70% of potential GLP-1 users cite needle aversion as a primary barrier to initiation. By eliminating that friction, Novo Nordisk has unlocked a demand pool that injectable formulations could never fully access.
Meanwhile, Eli Lilly's orforglipron (Foundayo™), the first oral small-molecule GLP-1 agonist, received FDA approval on April 1, 2026. Unlike semaglutide's peptide-based oral formulation, orforglipron is synthesized through conventional chemical manufacturing — a fundamentally different supply chain. The coexistence of oral peptide and oral small-molecule GLP-1 agents creates a dual-track API demand landscape that suppliers must navigate carefully.
The Wegovy pill is a modified peptide formulation using the SNAC enhancer technology developed by Emisphere. Manufacturing the oral semaglutide tablet requires not only the active peptide API — a complex 31-amino-acid chain produced via solid-phase peptide synthesis (SPPS) — but also a specialized enteric coating system and precise drug loading to ensure bioavailability in the gastrointestinal tract.
Goldman Sachs projects that global demand for semaglutide API will reach 8,500 kilograms by 2027, with oral formulations accounting for an estimated 35–40% of that volume. The oral route demands higher purity grades and tighter particle size distribution than injectable formulations, as even minor impurities or inconsistencies in peptide particle morphology can dramatically alter absorption profiles.
Current SPPS capacity is concentrated among a handful of manufacturers. Bachem, PolyPeptide Group, and several Chinese firms dominate the landscape. However, the 245% tariffs on Chinese-sourced APIs imposed in late 2025 have disrupted procurement patterns for Western pharmaceutical companies. Indian manufacturers like Neuland Laboratories are scaling up — reporting 47% year-over-year growth in peptide API revenues in Q3 FY2026 — but WHO GMP certification bottlenecks are delaying their entry into regulated markets.
The oral GLP-1 boom is not just an API story. The formulation requirements for oral peptide delivery are extraordinarily complex. SNAC co-formulation, enteric coating stability, and content uniformity across high-dose tablets all require specialized manufacturing capabilities that most CDMOs do not possess.
Novo Nordisk has invested over $4 billion in oral GLP-1 manufacturing infrastructure since 2024, including a dedicated tablet production facility in Kalundborg, Denmark. But the scale of demand — three million prescriptions in five months — suggests that even this capacity may prove insufficient. Contract manufacturers with enteric coating expertise and peptide handling capabilities are positioned to capture overflow demand.
For CDMOs like Catalent, Lonza, and Samsung Biologics' newly expanded Singapore facility, the oral GLP-1 opportunity represents a high-margin, high-complexity business segment. The formulation challenges are significant: semaglutide's stability in acidic gastric environments requires protective coating technologies that add cost and complexity but also create barriers to entry for less sophisticated manufacturers.
The FDA's PreCheck Pilot Program, launched in early 2026, is designed to streamline domestic pharmaceutical manufacturing facility development. While the program targets new U.S.-based facilities, its implications extend to the global supply chain. Companies with FDA PreCheck clearance will benefit from expedited regulatory review, potentially reducing the 18–24 month timeline for facility qualification by several months.
For peptide API and oral formulation suppliers, the PreCheck program creates both opportunity and urgency. Manufacturers who can demonstrate GMP compliance and supply chain resilience will be preferred partners for the major GLP-1 innovators. Those who cannot risk being excluded from the fastest-growing segment of the pharmaceutical market.
The oral GLP-1 market is entering a phase of exponential growth. Wegovy pill's three-million-prescription milestone is not an endpoint — it is the opening chapter. Novo Nordisk has indicated plans to launch Wegovy pill in select non-U.S. markets in H2 2026, and generic semaglutide tablet manufacturers are already preparing for post-patent-entry production. Dr. Reddy's Laboratories recently received CDSCO panel recommendation to manufacture and market oral semaglutide tablets in India.
For API suppliers, the message is clear: peptide manufacturing capacity — particularly SPPS-based production with GMP compliance for oral formulations — is the critical bottleneck. Companies that can offer validated, scalable peptide API supply with tight quality specifications will command premium pricing and long-term contracts.
For CDMO partners, the opportunity lies in formulation expertise. The oral peptide delivery challenge is not solved by API manufacturing alone. SNAC co-processing, tablet compression, enteric coating, and stability testing all require specialized infrastructure. CDMOs that can offer end-to-end oral GLP-1 manufacturing — from peptide API to finished tablet — will capture disproportionate value in the years ahead.
The oral GLP-1 era has arrived. The question for suppliers is not whether demand will grow, but whether they can scale fast enough to meet it.
